CD­MO Ster­ling ac­quires ADC Bio, ramp­ing up ca­pac­i­ty for an­ti­body-drug con­ju­gate man­u­fac­tur­ing work

Ster­ling Phar­ma So­lu­tions has an­nounced the ac­qui­si­tion of ADC Bio, a UK-based com­pa­ny that spe­cial­izes in an­ti­body drug con­ju­gates. ADC’s Wales man­u­fac­tur­ing fa­cil­i­ty will re­brand to be­come part of the Ster­ling net­work, the com­pa­nies said.

ADC will start work as part of the Ster­ling net­work as ear­ly as 2022. The move al­lows Ster­ling to in­te­grate the new fa­cil­i­ty’s high­ly po­tent API ca­pa­bil­i­ties to de­vel­op and man­u­fac­ture tox­in link­ers, ac­cord­ing to a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER